Finance

Beta
Lists
CYTK:NASDAQ
Cytokinetics, Inc.
$79.46
+0.37%
(+0.29) 1D
Jun 23, 11:05:29 AM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CYTK...
Open
$78.99
High
$80.40
Low
$78.27
Mkt. cap
10.80B
Avg. vol.
2.26M
Volume
410.65K
52-wk high
$80.80
52-wk low
$32.22
EPS
-$6.84
Beta
0.42
Shares outstanding
124.43M
No. of employees
673
Open
$78.99
High
$80.40
Low
$78.27
Mkt. cap
10.80B
Avg. vol.
2.26M
Volume
410.65K
52-wk high
$80.80
52-wk low
$32.22
EPS
-$6.84
Beta
0.42
Shares outstanding
124.43M
No. of employees
673
News stories
From sources across the web
Profile
Cytokinetics, Incorporated, is a biopharmaceutical company based in South San Francisco, California, that develops muscle activators and muscle inhibitors as potential treatments for people with diseases characterized by impaired or declining muscle function. Wikipedia
About Cytokinetics, Inc.
CEORobert I. Blum | Robert I. Blum
Employees673
Founded1997
HeadquartersSouth San Francisco, California, United States
SectorBiotechnology
Websitecytokinetics.com
Analyst Ratings
Based on 16 analysts giving stock ratings to CYTK in the past 3 months
Strong Buy
Buy
13
Hold
3
Sell
0
12 month forecast
Based on 16 Wall Street analysts offering 12 month price targets for CYTK in the last 3 months.
Highest
Current $79.46
$140.00 (+76.19%)
Average
$100.93 (+27.02%)
Lowest
$69.00 (-13.16%)
Analyst
Recommendation
Action
Price Target
Projected
Date
Salim Syed
Mizuho Securities
Buy
Maintained
$118.00
+48.5%
06/23/2026
Eric Joseph
Citi
Buy
Reiterated
$99.00
+24.6%
06/16/2026
Maxwell Skor
Morgan Stanley
Buy
Maintained
$103.00
+29.6%
06/16/2026
Jason Zemansky
Bank of America Securities
Hold
Maintained
$83.00
+4.5%
06/16/2026
Serge Belanger
Needham
Buy
Maintained
$102.00
+28.4%
06/16/2026
Tessa Romero
J.P. Morgan
Buy
Maintained
$97.00
+22.1%
06/05/2026
Unknown Analyst
Citi
Buy
Initiated
$99.00
+24.6%
05/19/2026
Joseph Pantginis
H.C. Wainwright
Buy
Reiterated
$140.00
+76.2%
05/12/2026
Yanan Zhu
Wells Fargo
Buy
Maintained
$105.00
+32.1%
05/07/2026
James Condulis
Stifel Nicolaus
Buy
Reiterated
$108.00
+35.9%
05/06/2026
Unknown Analyst
Raymond James
Hold
Maintained
-
-
05/06/2026
Yasmeen Rahimi
Piper Sandler
Buy
Maintained
$107.00
+34.7%
05/06/2026
Leonid Timashev
RBC Capital
Buy
Maintained
$119.00
+49.8%
05/05/2026
Paul Choi
Goldman Sachs
Buy
Reiterated
$101.00
+27.1%
05/05/2026
Srikripa Devarakonda
Truist Financial
Buy
Reiterated
$106.00
+33.4%
05/06/2026
Emily Field
Barclays
Buy
Reiterated
$95.00
+19.6%
04/06/2026
Cory Kasimov
Evercore ISI
Buy
Maintained
$80.00
+0.7%
04/01/2026
Ashwani Verma
UBS
Hold
Maintained
$69.00
-13.2%
03/24/2026
Mayank Mamtani
B. Riley Securities
Buy
Reiterated
$108.00
+35.9%
03/10/2026
Carter Gould
Cantor Fitzgerald
Buy
Maintained
-
-
02/25/2026
Jason Butler
Citizens JMP
Buy
Maintained
$96.00
+20.8%
02/25/2026
Last report
May 5, 2026
Fiscal period
Q1 2026
EPS / Est. (USD)
-$1.67 / -$1.65
-1.16%miss
Revenue / Est. (USD)
19.36M / 9.08M
+113.25%beat
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
66.77M
1.94M
17.76M
19.36M
Cost of goods sold
112.55M
99.23M
104.40M
95.68M
Cost of revenue
112.55M
99.23M
104.40M
95.68M
Research and development expenses
-
-
-
2.39M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
65.72M
69.46M
91.72M
104.90M
Operating expense
65.72M
69.46M
91.72M
107.29M
Total operating expenses
178.28M
168.69M
196.12M
202.97M
Operating income
-111.51M
-166.76M
-178.37M
-183.62M
Other non operating income
-11.60M
-2.10M
14.20M
-100.00K
EBT including unusual items
-134.37M
-306.18M
-183.03M
-206.03M
EBT excluding unusual items
-134.37M
-184.93M
-183.03M
-206.03M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-134.37M
-306.18M
-183.03M
-206.03M
Net profit margin
-201.25%
-15,814.98%
-1,030.87%
-1,064.48%
Earnings per share
-1.12
-1.54
-1.50
-1.67
Interest and investment income
13.00M
10.25M
11.47M
11.02M
Interest expense
-24.26M
-26.32M
-30.34M
-33.34M
Net interest expenses
-11.26M
-16.07M
-18.86M
-22.31M
Depreciation and amortization charges
-
-
-
-
EBITDA
-109.22M
-164.08M
-175.50M
-180.24M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer